Updates in the Diagnosis and Management of AL Amyloidosis

AbstractPurpose of ReviewLight chain (AL) amyloidosis is an insidious progressive disease which results in significant morbidity and inevitable mortality if not diagnosed and treated promptly. This review will highlight recent developments and summarize critical clinical points and updated practice changes for the clinician in 2020.Recent FindingsComparative analyses of staging systems, updated prognostic tools, and treatment response criteria now allow for improved patient stratification and treatment decisions; the role of minimal residual disease in response assessment is still being assessed. Clinical and genetic predictors for long-term survivors have been highlighted. Standard-of-care front-line bortezomib and the integration of anti-CD38 monoclonal antibodies in the relapsed disease have transformed treatment approach in recent years. Various clinical trials in the pipeline include novel anti-plasma cell therapies and therapies directed against amyloid deposits which promise to further advance the treatment landscape.SummaryDiagnosis, response assessment, and treatment paradigms for AL amyloidosis have evolved significantly in the past 15  years, translating into superior outcomes and increased chances of long-term survival for AL amyloidosis.
Source: Current Hematologic Malignancy Reports - Category: Hematology Source Type: research